Urinary neopterin levels in patients with major depressive disorder and panic disorder who do not receive pharmacologic treatment

被引:0
|
作者
Taymur, Ibrahim [1 ]
Ozen, Nurper Erberk [2 ]
Boratav, Riza Cumhur [3 ]
Yaman, Halil [4 ]
机构
[1] Diskapi YB Egitim & Arastirma Hastanesi, Saglik Bakanligi, Ankara, Turkey
[2] Ufuk Univ, Tip Fak, Ruh Sagligi & Hastaliklari ABD, Ankara, Turkey
[3] Composmentis Psikiyatri Arastirma Merkezi, Ankara, Turkey
[4] Gulhane Askeri Tip Akad, Tibbi Biyokimya ABD, Ankara, Turkey
关键词
neopterine; depression; panic disorder; tetrahydrobiopterine; PLASMA TETRAHYDROBIOPTERIN LEVELS; DEXAMETHASONE-SUPPRESSION TEST; POSTTRAUMATIC-STRESS-DISORDER; SERUM NEOPTERIN; BIOPTERIN; TRYPTOPHAN; THERAPY; PATHOPHYSIOLOGY; METABOLISM; INVENTORY;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To measure urinary level of pterine which takes place in synthesis of monoamine in major depressive disorder and panic disorder patiens and compare results with healthy group. Methods: Fourteen patients with panic disorder, 26 patients with major depressive disorder and 20 healthy volunteers were included to the study. Beck Depression Inventory, Beck Anxiety Inventory, Panic-Agoraphobia Scale, State-Trait Anxiety Inventory were applied to patients in order to evaluate severity of disorders. Results: Measurement results of neopterin levels were 199.6 +/- 90.8 mu mol/creatinine in depressive disorder group, 182.9 +/- 68.0 mu mol/creatinin panic disorder group and 181.4 +/- 202.8 mu mol/creatinin in control group (p=0.030). Neopterin level in depressive disorder is significantly higher than control group (p=0.015). Conclusion: Tetrahydrobiopterin (BH4) is cofactor of tyrosine hydroxylase and tryptophan hydroxylase, the rate limiting enzymes in synthesis of serotonin, noradrenaline and dopamine from tyrosine and tryptophan. Rise in plasma levels of neopterine means activation in BH4 synthesis and reduction in monoamine levels. According to the results our study, changes in neopterine and BH4 levels may have influence in appearing depressive disorder more than panic disorder. (Anatolian Journal of Psychiatry 2011; 12:7-12)
引用
收藏
页码:7 / 12
页数:6
相关论文
共 50 条
  • [31] Gender difference in clinical factors associated with comorbid major depressive disorder in patients with panic disorder
    Oh, K. S.
    Lee, D. W.
    Lim, S. W.
    ASIA-PACIFIC PSYCHIATRY, 2015, 7 : 25 - 25
  • [32] THE PREVALENCE OF RESPIRATORY DISORDERS IN PANIC DISORDER, MAJOR DEPRESSIVE DISORDER AND V-CODE PATIENTS
    SPINHOVEN, P
    ROS, M
    WESTGEEST, A
    VANDERDOES, AJW
    BEHAVIOUR RESEARCH AND THERAPY, 1994, 32 (06) : 647 - 649
  • [33] Heart rate variability in drug-naive patients with panic disorder and major depressive disorder
    Kikuchi, Mitsuru
    Hanaoka, Akira
    Kidani, Tomokazu
    Remijn, Gerard Bastiaan
    Minabe, Yoshio
    Munesue, Toshio
    Koshino, Yoshifumi
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (08): : 1474 - 1478
  • [34] Clinical characteristics and heart rate variability in patients comorbid panic disorder with major depressive disorder
    Choi, Y.
    Kim, M. S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S217 - S217
  • [35] Effects of Age on Paroxetine Efficacy in Patients With Major Depressive Disorder Who Do Not Exhibit an Early Response to Treatment
    Tomita, Tetsu
    Sato, Yasushi
    Nakagami, Taku
    Tsuchimine, Shoko
    Kaneda, Ayako
    Kaneko, Sunao
    Nakamura, Kazuhiko
    Yasui-Furukori, Norio
    CLINICAL NEUROPHARMACOLOGY, 2015, 38 (01) : 6 - 10
  • [36] URINARY NEOPTERINE LEVELS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: ALTERATIONS AFTER TREATMENT WITH PAROXETINE AND COMPARISON WITH HEALTHY CONTROLS
    Taymur, Ibrahim
    Ozdel, Kadir
    Ozen, Nurper Erberk
    Gungor, Buket Belkiz
    Atmaca, Murad
    PSYCHIATRIA DANUBINA, 2015, 27 (01) : 25 - 30
  • [37] Investigation of Irisin Levels in Patients with Major Depressive Disorder
    Okumus, Burak
    Pusuroglu, Meltem
    Baltacioglu, Mehmet
    Bahceci, Ilkay
    Bahceci, Buelent
    PSYCHIATRY AND BEHAVIORAL SCIENCES, 2024, 14 (01): : 40 - 47
  • [38] INTEGRATIVE TREATMENT STRATEGIES OF PANIC DISORDER WITH AGORAPHOBIA AND DEPRESSIVE DISORDER
    BOERNER, RJ
    NERVENARZT, 1995, 66 (03): : 212 - 216
  • [39] Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment
    Kim, Helena Kyunghee
    Tyryshkin, Kathrin
    Elmi, Nika
    Dharsee, Moyez
    Evans, Kenneth R.
    Good, Jennifer
    Jayadi, Mojib
    McCormack, Stephanie
    Vaccarino, Anthony L.
    Zhang, Xiao
    Andreazza, Ana Cristina
    Feilotter, Harriet
    JOURNAL OF PSYCHIATRIC RESEARCH, 2019, 110 : 38 - 44
  • [40] MAJOR DEPRESSIVE DISORDER AND PANIC DISORDER - EFFECTS OF CO-MORBIDITY ON TREATMENT OUTCOME WITH ANTIDEPRESSANT MEDICATIONS
    GRUNHAUS, L
    HAREL, Y
    KRUGLER, T
    PANDE, AC
    HASKETT, RF
    CLINICAL NEUROPHARMACOLOGY, 1988, 11 (05) : 454 - 461